FORMA therapeutics and Cancer Research Technology to discover cancer drugs targeting deubiquitinating enzymes (DUBs)

LMB’s David Komander is part of collaborative consortium including FORMA Therapeutics and Cancer Research Technology, aiming to discover cancer drugs targeting deubiquitinating enzymes (DUBs). More…